CCDC7

Summary

CCDC7 (coiled-coil domain containing 7, HGNC:26533) is a protein-coding gene on chromosome 10p11.22, encoding Coiled-coil domain-containing protein 7 (Q96M83). May play a role in tumorigenesis.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 85 total
• MANE Select transcript: NM_001395015

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26533
Approved symbol	CCDC7
Name	coiled-coil domain containing 7
Location	10p11.22
Locus type	gene with protein product
Status	Approved
Aliases	FLJ32762, FLJ13031, BIOT2
Ensembl gene	ENSG00000216937
Ensembl biotype	protein_coding
OMIM	619444
Entrez	79741

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 7 protein_coding, 4 nonsense_mediated_decay, 4 protein_coding_CDS_not_defined

ENST00000277657, ENST00000302316, ENST00000362006, ENST00000375025, ENST00000375028, ENST00000476558, ENST00000537047, ENST00000539197, ENST00000545067, ENST00000638889, ENST00000639041, ENST00000639290, ENST00000639453, ENST00000639629, ENST00000640058

RefSeq mRNA: 4 — MANE Select: NM_001395015 NM_001026383, NM_001321115, NM_001395015, NM_145023

CCDS: CCDS7173, CCDS86081

Canonical transcript exons

ENST00000639629 — 44 exons

Exon	Start	End
ENSE00001627609	32453344	32453436
ENSE00001628496	32463017	32463049
ENSE00001730290	32462683	32462703
ENSE00001745567	32711620	32711730
ENSE00001757795	32456251	32456334
ENSE00001775828	32694879	32694992
ENSE00003230374	32814370	32814453
ENSE00003235566	32824518	32824604
ENSE00003238292	32845243	32845326
ENSE00003246136	32854400	32854489
ENSE00003283598	32778977	32779084
ENSE00003293246	32729332	32729457
ENSE00003310879	32664054	32664161
ENSE00003328162	32848596	32848718
ENSE00003367103	32726734	32726832
ENSE00003372093	32851807	32851932
ENSE00003382152	32845543	32845626
ENSE00003383149	32847833	32847916
ENSE00003387525	32689053	32689163
ENSE00003389880	32846376	32846459
ENSE00003404946	32834815	32834898
ENSE00003441864	32805015	32805098
ENSE00003446722	32845876	32845959
ENSE00003472085	32491922	32491997
ENSE00003490532	32471064	32471230
ENSE00003529013	32472481	32472542
ENSE00003569975	32567670	32567891
ENSE00003570210	32543300	32543385
ENSE00003621875	32565558	32565620
ENSE00003626757	32517945	32517975
ENSE00003658393	32544247	32544301
ENSE00003676606	32473967	32474023
ENSE00003802929	32876347	32876580
ENSE00003802996	32446140	32446397
ENSE00003808896	32635057	32635158
ENSE00003809258	32584232	32584304
ENSE00003810949	32571859	32571893
ENSE00003811233	32634254	32634364
ENSE00003811275	32583034	32583307
ENSE00003961160	32882693	32882864
ENSE00003963353	32451592	32451921
ENSE00003963359	32728887	32728997
ENSE00003963360	32685970	32686080
ENSE00003963362	32518416	32518505

Expression profiles

Bgee: expression breadth ubiquitous, 194 present calls, max score 97.04.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.3652 / max 175.4721, expressed in 1587 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104624	3.2919	1231
104625	1.6193	811
104626	1.4540	614

Top tissues by expression

266 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	97.04	gold quality
left testis	UBERON:0004533	96.57	gold quality
sperm	CL:0000019	96.43	gold quality
right testis	UBERON:0004534	96.05	gold quality
sural nerve	UBERON:0015488	95.05	gold quality
male germ cell	CL:0000015	95.02	gold quality
testis	UBERON:0000473	93.77	gold quality
tendon	UBERON:0000043	91.68	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.34	gold quality
tendon of biceps brachii	UBERON:0008188	87.73	gold quality
colonic epithelium	UBERON:0000397	85.79	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.26	gold quality
adrenal tissue	UBERON:0018303	82.04	gold quality
medial globus pallidus	UBERON:0002477	80.94	gold quality
corpus callosum	UBERON:0002336	76.25	gold quality
cortical plate	UBERON:0005343	75.18	gold quality
diaphragm	UBERON:0001103	75.10	gold quality
popliteal artery	UBERON:0002250	73.96	gold quality
tibial artery	UBERON:0007610	73.95	gold quality
granulocyte	CL:0000094	73.64	gold quality
bone marrow cell	CL:0002092	73.59	gold quality
ascending aorta	UBERON:0001496	73.51	gold quality
aorta	UBERON:0000947	73.49	gold quality
globus pallidus	UBERON:0001875	73.45	gold quality
artery	UBERON:0001637	73.39	gold quality
thoracic aorta	UBERON:0001515	73.32	gold quality
hindlimb stylopod muscle	UBERON:0004252	73.27	gold quality
tibial nerve	UBERON:0001323	73.23	gold quality
leukocyte	CL:0000738	73.19	gold quality
adenohypophysis	UBERON:0002196	73.18	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	7.73
E-ANND-3	no	6.48

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1

miRNA regulators (miRDB)

13 targeting CCDC7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-887-5P	98.82	65.90	1347
HSA-MIR-4686	98.77	66.87	964
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-30C-1-3P	97.80	66.36	1499
HSA-MIR-30C-2-3P	97.80	66.45	1499
HSA-MIR-6788-5P	97.80	66.41	1532
HSA-MIR-6828-3P	96.06	67.61	1155
HSA-MIR-6777-3P	95.35	64.30	699

Literature-anchored findings (GeneRIF, showing 2)

• Overexpression of hBiot2 is associated with early and interim development of human cervical cancer. (PMID:21109960)
• A higher expression of hBiot2 in primary CRC patients independently indicates a poorer prognosis. (PMID:22024937)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Coiled-coil domain-containing protein 7 — Q96M83 (reviewed: Q96M83)

Alternative names: Protein BIOT2

All UniProt accessions (9): Q96M83, A0A096LNG8, A0A0A6YYA4, A0A1B0GWZ1, A0A1W2PNE7, A0A384NKY2, A6YT98, A6YT99, A6YTA0

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in tumorigenesis.

Tissue specificity. Expressed in epithelium of normal cervix and cervical cancer. Overexpressed in early and interim cervical cancer.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (5)

UniProt ID	Names	Canonical?
Q96M83-1	1	yes
Q96M83-2	2
Q96M83-3	3
Q96M83-4	4
Q96M83-5	5

RefSeq proteins (4): NP_001021554, NP_001308044, NP_001381944, NP_659460 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029272	CCDC7	Family

Pfam: PF15368

UniProt features (36 total): compositionally biased region 14, splice variant 8, sequence variant 5, region of interest 4, sequence conflict 2, coiled-coil region 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96M83-F1	43.53	0.02

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 46 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_DN, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GEORGES_TARGETS_OF_MIR192_AND_MIR215, chr10p11, ZWANG_DOWN_BY_2ND_EGF_PULSE, GSE13522_WT_VS_IFNG_KO_SKING_T_CRUZI_Y_STRAIN_INF_UP, CREB3L4_TARGET_GENES, ELF2_TARGET_GENES, GLI3_TARGET_GENES, NCOA6_TARGET_GENES, NPAT_TARGET_GENES, SKIL_TARGET_GENES, UBN1_TARGET_GENES, CASP8AP2_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

552 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC7	E5RHQ9	E5RHQ9	418
CCDC7	CCDC136	Q96JN2	415
CCDC7	KIAA0586	Q9BVV6	405
CCDC7	TMA7	Q9Y2S6	402
CCDC7	ODAD1	Q96M63	380
CCDC7	ANKRD18B	A2A2Z9	379
CCDC7	YEATS2	Q9ULM3	375
CCDC7	CYCS	P00001	374
CCDC7	ZNF732	B4DXR9	371
CCDC7	CEP120	Q8N960	359
CCDC7	ARL17B	I3L3L1	352
CCDC7	NOL4	O94818	351
CCDC7	ARL17A	Q8IVW1	348
CCDC7	RLF	Q13129	348
CCDC7	LRRC49	Q8IUZ0	348

IntAct

10 interactions, top by confidence:

A	B	Type	Score
CCDC7	PLXNA1	psi-mi:“MI:0915”(physical association)	0.400
CCDC7	KLHL20	psi-mi:“MI:0915”(physical association)	0.400
CCDC7	ITGA6	psi-mi:“MI:0915”(physical association)	0.400
CIAO1	CCDC7	psi-mi:“MI:0915”(physical association)	0.370
EWSR1	CCDC7	psi-mi:“MI:0915”(physical association)	0.370
CCDC7	ZDHHC17	psi-mi:“MI:0915”(physical association)	0.370
APBB1	SSPOP	psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350

BioGRID (31): CCDC7 (Two-hybrid), CCDC7 (Two-hybrid), CCDC7 (Two-hybrid), CCDC7 (Affinity Capture-RNA), CCDC7 (Affinity Capture-MS), CCDC7 (Synthetic Lethality), CCDC7 (Affinity Capture-MS), CCDC7 (Two-hybrid), PLXNA1 (Proximity Label-MS), CCDC7 (Proximity Label-MS), KLHL20 (Proximity Label-MS), CCDC7 (Affinity Capture-MS), CCDC7 (Affinity Capture-MS), HIST1H1C (Cross-Linking-MS (XL-MS)), CCDC7 (Protein-peptide)

ESM2 similar proteins: A0A1B0GVN3, A1KXM5, A2AEY4, A6NFE2, A6QQS3, A7A061, A7KBS4, A8MTZ7, B3LRH6, B4HGK2, B4QT24, B5VMP2, E1JH25, F4KIH4, F6XZJ7, O36020, O49498, O74981, O94713, O96001, P21691, P22575, P88825, Q11194, Q2YDJ5, Q32MG2, Q3URS2, Q4V8E9, Q5BB76, Q5JRM2, Q5R7U0, Q5RDG2, Q6AXV6, Q6AXY9, Q6P1M9, Q6PI77, Q80VJ6, Q810T2, Q8BUY8, Q8NA61

Diamond homologs: Q95J40, Q96M83, Q9D541

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

85 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	65
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3586 predictions. Top by Δscore:

Variant	Effect	Δscore
10:32446290:G:GT	donor_gain	1.0000
10:32451918:GATG:G	donor_gain	1.0000
10:32451923:T:A	donor_loss	1.0000
10:32453340:A:AG	acceptor_gain	1.0000
10:32453340:ACAG:A	acceptor_gain	1.0000
10:32453341:C:G	acceptor_gain	1.0000
10:32453342:A:AG	acceptor_gain	1.0000
10:32453342:AG:A	acceptor_gain	1.0000
10:32453342:AGGTT:A	acceptor_gain	1.0000
10:32453343:G:GT	acceptor_gain	1.0000
10:32453343:GG:G	acceptor_gain	1.0000
10:32453343:GGT:G	acceptor_gain	1.0000
10:32453343:GGTT:G	acceptor_gain	1.0000
10:32453343:GGTTG:G	acceptor_gain	1.0000
10:32453432:TATCT:T	donor_gain	1.0000
10:32453433:ATCT:A	donor_gain	1.0000
10:32453434:TCT:T	donor_gain	1.0000
10:32453435:CT:C	donor_gain	1.0000
10:32453436:TG:T	donor_loss	1.0000
10:32453437:G:GG	donor_gain	1.0000
10:32453437:G:T	donor_loss	1.0000
10:32453438:T:A	donor_loss	1.0000
10:32453441:G:GG	donor_gain	1.0000
10:32456335:G:GG	donor_gain	1.0000
10:32471231:G:GG	donor_gain	1.0000
10:32543273:A:AG	acceptor_gain	1.0000
10:32543274:T:G	acceptor_gain	1.0000
10:32543278:T:A	acceptor_gain	1.0000
10:32543279:G:A	acceptor_gain	1.0000
10:32543285:T:G	acceptor_gain	1.0000

AlphaMissense

9145 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:32451914:T:C	L91P	0.994
10:32567673:G:C	A401P	0.991
10:32565612:G:C	A397P	0.989
10:32463020:T:C	F161L	0.985
10:32463022:T:A	F161L	0.985
10:32463022:T:G	F161L	0.985
10:32518483:T:C	L324P	0.981
10:32565592:T:C	L390P	0.980
10:32567695:T:C	L408P	0.978
10:32462696:T:C	L157P	0.977
10:32456306:T:C	L143P	0.976
10:32451800:T:C	L53P	0.975
10:32471170:T:C	L206P	0.975
10:32463017:T:A	W160R	0.973
10:32463017:T:C	W160R	0.973
10:32491981:G:C	A286P	0.973
10:32451839:C:A	A66D	0.972
10:32491969:T:C	F282L	0.972
10:32491971:T:A	F282L	0.972
10:32491971:T:G	F282L	0.972
10:32473969:T:C	F248L	0.970
10:32473971:C:A	F248L	0.970
10:32473971:C:G	F248L	0.970
10:32451838:G:C	A66P	0.968
10:32463021:T:C	F161S	0.965
10:32567682:G:C	A404P	0.964
10:32518471:T:C	L320P	0.963
10:32565604:T:C	L394S	0.958
10:32456314:G:C	A146P	0.957
10:32565571:T:C	L383P	0.953

dbSNP variants (sampled 300 via entrez): RS1000013295 (10:32657887 A>G), RS1000024535 (10:32644514 A>T), RS1000027578 (10:32473057 A>G), RS1000028812 (10:32603695 G>A), RS1000029192 (10:32564441 C>T), RS1000049003 (10:32862116 T>C), RS1000057543 (10:32781255 C>A), RS1000064985 (10:32758547 A>C,T), RS1000067526 (10:32705875 C>G), RS1000070292 (10:32494596 C>T), RS1000075002 (10:32667052 T>C,G), RS1000082377 (10:32871394 G>A), RS1000084293 (10:32811668 C>G), RS1000084589 (10:32480540 A>G), RS1000086840 (10:32571054 G>A)

Disease associations

OMIM: gene MIM:619444 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002699_2	Suicide in bipolar disorder	2.000000e-06
GCST003264_259	Post bronchodilator FEV1/FVC ratio	4.000000e-06
GCST010320_45	PR interval	2.000000e-08
GCST010321_20	PR interval	5.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006882	suicide behaviour measurement
EFO:0004713	FEV/FVC ratio
EFO:0004462	PR interval

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 0 entries

CTD chemical–gene interactions

11 total (human), top 11 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
triphenyl phosphate	affects expression	1
butyraldehyde	decreases expression	1
CGP 52608	affects binding, increases reaction	1
Grape Seed Proanthocyanidins	decreases expression, affects cotreatment	1
Sunitinib	increases expression	1
Cannabidiol	decreases expression	1
Catechin	affects cotreatment, decreases expression	1
Methotrexate	increases expression	1
Tretinoin	decreases expression	1
Cadmium Chloride	increases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome